At TNI BioTech, Inc., our goal is to benefit patients with chronic and often life-threatening diseases through the activation and rebalancing of the body's immune system using our patented immunotherapy.
Our products, technologies, and patents are designed to harness the power of the immune system to improve the treatment of cancer and infections, such as HIV/AIDS and autoimmune diseases. We are currently developing active and adoptive forms of immunotherapies.
Our most advanced clinical programs involve immunotherapy with methionine-enkephalin (MENK) or low dose naltrexone, which both work by triggering opioid receptors on immune cells and lead to an activation and expansion of various cells in the immune system.
Spleen mononuclear cells of BALB/C mice and YAC-1 cells were used in this experiment.
Leucine enkephalin or methionine enkephalin at time 0 was added to cell cultures and the amount of the enzyme lactate dehydrogenase released from lysed target cells was determined 22 hours after incubation. There were on average 41% (5% to 60.7%) and 63% (46.8% to 78%) enhancements of natural killer activity in the presence of leucine enkephalin (1 x 10(-11)-1 x 10(-3) mg/ml) and methionine enkephalin (1 x 10(-15)-1 x 10(-3) mg/ml) respectively. The results showed that opioid peptides can modify NK cell function.